Group 1: Bristol-Myers Squibb (BMY) - Bristol-Myers Squibb (BMY) is expected to benefit from a potential capital rotation towards long-duration, cash-generative equities if interest rates remain lower or stable in 2026 [3] - The stock has reclaimed its 200-month moving average and a long-term trendline, with potential upside of nearly 18% to test March 2025 highs of $63, and up to 40% towards a former long-term high of $75 within the next 12 months [5] Group 2: Cameco (CCJ) - Cameco is experiencing increased demand due to the growing interest in nuclear power as an alternative energy source, supported by geopolitical factors and the AI industry's growth [6] - The stock has risen over 80% year-to-date after breaking out of a trading range, indicating potential for further upward movement [8] Group 3: GigaCloud Technology (GCT) - GigaCloud Technology (GCT) has shown significant growth, breaking through a downtrend and achieving a 112% lead for the year, supported by its 20-day moving average [9] - The stock reached a new 52-week peak in December, significantly above its IPO price, with potential for further analyst attention and a possible short squeeze due to a notable percentage of shares sold short [11] Group 4: Baidu (BIDU) - Baidu has seen over 40% growth in 2025, marking a turnaround after years of underperformance, with momentum expected to continue into 2026 [12] - The stock's 20-week moving average has crossed above its 200-week moving average for the first time since 2020, indicating a positive long-term trend [12]